@FiercePharma: Top news online yesterday: J&J hikes earnings forecast on pharma's superhero sales flight. Story | Follow @FiercePharma
@EricPFierce: MHRA says it also took action against Wockhardt contractor Nestor in U.K. as part of recent action. Article from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: Look out, Vivus--Eisai to double Belviq sales force by December 2013. Release | Follow @CarlyHFierce
> Johnson & Johnson ($JNJ) was negligent in warning expectant mothers of the risk of birth defects with its seizure drug Topamax, a lawyer for one woman said, as a trial over her son's cleft palate began. Report
> The FDA said another generic version of Wellbutrin XL, this one from Actavis ($ACT), would be pulled off the market because it is not bioequivalent to the branded drug. Report
> Health Canada said it will better communicate the risks of recalled drugs after a report criticized its handling of Apotex's recall of its birth control pill Alysena 28. Report
> The U.S. Supreme Court declined to hear the case of a woman who sought to hold Hospira ($HSP) liable for a shortage of its injectable drug Aquasol A. Report
> Russia's pharmaceuticals sales are expected to grow by 11% this year, to $130.4 billion, the market research firm Business Monitor says. Report
> Florida prison officials executed a man using the sedative midazolam hydrochloride as part of a three-drug cocktail; the drug had not been used in previous executions. Report
@FierceMedDev: ICYMI yesterday: FierceMedicalDevices' 2013 Fierce 15. Feature | Follow @FierceMedDev
> TB Dx maker Oxford Immunotec to pursue IPO path. Report
> Myriad vs. Quest over BRCA testing: It's getting serious. More
> Abbott posts med tech growth thanks to diagnostics, dealmaking. Story
Biotech News
@FierceBiotech: ICYMI yesterday: The top Phase III R&D setbacks of 2013. Feature | Follow @FierceBiotech
@JohnCFierce: Third Rock startup banks $20M to fuel next leg of CNS drug development journey. News | Follow @JohnCFierce
@DamianFierce: St. Jude boosts profits as job cuts, M&A pay off. Article | Follow @DamianFierce
@EmilyMFierce: Georgetown University Medical Center researchers find a vegetable-based compound that protects against side effects of radiation therapy. Article from FierceBiotech Research | Follow @EmilyMFierce
> Is Eli Lilly about to start cutting its blockbuster R&D budget? More
> MedImmune leads $12.5M round for new drug aimed at big chemo market. Article
> Sanofi, Regeneron take the lead in blockbuster PhIII race of PCSK9 drugs. Story
Biomarkers News
> Biomarker differentiates ADHD subtypes, offers clues for treatment. Article
> Amgen taps KineMed for Alzheimer's biomarkers. Report
> Skin may conceal a viable Parkinson's biomarker. Story
Drug Delivery News
@MichaelGFierce: AstraZeneca teams with Taris to research bladder cancer delivery device. Story | Follow @MichaelGFierce
> Mini-pancreas grown from stem cells has implications for future insulin delivery. More
> Cell membrane models 'written' on graphene provide drug-delivery model. Item
> Study: Synthetic RNA conjugates target, silence bacteria's genetic material. Article
> Nanoparticle hydrogel heats up to release drugs in active cartilage. Story
Diagnostics News
@MarkHFierce: Smith & Nephew will handle U.S. distribution of a women's care diagnostic device developed by Femasys. Story | Follow @MarkHFierce
> Applied Proteomics to develop pancreatic and colon cancer Dx with German research institute. More
> Quest preemptively sues Myriad to ensure new BRCA test avoids patent violation. Report
> CardioDx's proposed $86.2M IPO will aid marketing and insurance coverage efforts. Story
> New blood test screens for irritable bowel syndrome. Article
> Mount Sinai's Icahn School of Medicine jumps into Dx, drug development. Item
And Finally... U.S. regulators are set to consider whether a "three-parent" reproductive technique should be tested as a way to keep genetic defects from passing from mothers to children. Report